METHODS	We examined the effect of prior CVA/TIA or PAD ( extra-cardiac vascular disease [ EVD ] ) on the outcome of 10,281 patients with acute coronary syndromes enrolled in the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis in Myocardial Infarction ( OPUS-TIMI ) 16 trial of the oral glycoprotein IIb/IIIa antagonist orbofiban plus aspirin versus aspirin alone .\